Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.TorreyPines Therapeutics has signed an exclusive license agreement with Johns Hopkins University for intellectual property related to the novel use of glutamate receptor antagonists, including tezampanel and NGX426, for the prevention and treatment of stroke, heart attack and other conditions associated with increased platelet aggregation.
Subscribe to our email newsletter
The intellectual property is based on research conducted in the JHU laboratories of Craig Morrell and Charles Lowenstein that demonstrates the importance of glutamate release in promoting platelet activation and thrombosis and which identifies the AMPA receptors on platelets as a new antithrombotic target.
Tezampanel, given subcutaneously, and NGX426, given orally, are currently being developed by TorreyPines Therapeutics for the treatment of acute migraine and chronic pain.
Neil Kurtz, president and CEO of TorreyPines, said: “This is breakthrough research that further illustrates the importance of glutamate receptors as a new target for a wide range of indications. Additionally, the findings underscore the versatility and commercial prospects for our lead AMPA/kainate receptor antagonists, tezampanel and NGX426.”